#Ribo Life Science #Ribocure Pharmaceuticals #Madrigal Pharmaceuticals

Ribo and Ribocure Partner with Madrigal to Combat MASH

Suzhou Ribo Life Science Co., Ltd., publicly traded on the Hong Kong Stock Exchange under the symbol 06938, along with its subsidiary Ribocure Pharmaceuticals AB, has recently announced a significant licensing agreement with Madrigal Pharmaceuticals, Inc. This agreement grants Madrigal the exclusive worldwide license for six preclinical small-interfering RNA (siRNA) programs aimed at treating metabolic dysfunction-associated steatohepatitis (MASH).

In a statement released on February 12, 2026, the collaboration is hailed as a pivotal moment for Ribo and Ribocure, as they plan to utilize Ribo's validated siRNA GalSTARTM platform, which specifically targets the liver, to develop novel treatment solutions for MASH. The current licensing deal encompasses several of Ribo's pre-existing preclinical assets. Furthermore, both companies retain the potential to expand this collaboration to include new siRNA programs, including bispecific siRNAs designed to target two disease-causing genes simultaneously, leveraging Ribo's unique GalSTARTM and siRNA platforms for chemical modifications.

Strategic Vision and Potential Impact
Dr. Zicai Liang, CEO of Ribo, expressed his enthusiasm for the partnership, stating that combining Madrigal's extensive knowledge with Ribo's siRNA expertise could lead to transformative therapies for patients suffering from liver diseases.